Gastroesophageal Reflux Disease Clinical Trial
Official title:
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic Gastroesophageal Reflux Disease Not Completely Responsive to Proton Pump Inhibitors
Verified date | October 2019 |
Source | Ironwood Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objectives of this study are to evaluate the safety, efficacy, and dose-response relationship of IW-3718 administered orally to participants who have GERD and continue to experience GERD symptoms while receiving once-daily (QD), standard-dose proton pump inhibitors (PPIs).
Status | Completed |
Enrollment | 282 |
Est. completion date | April 26, 2017 |
Est. primary completion date | April 26, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patient is an ambulatory, community-dwelling male or nonpregnant female and is at least 18 years old at the Screening Visit. Lactating females must agree not to breastfeed. - Patient has a diagnosis of GERD and reports experiencing GERD symptoms (heartburn or regurgitation) on = 4 days per week during the 8 weeks before the Screening Visit while taking standard QD PPI therapy. Exclusion Criteria: - Patient may not meet any of the excluded conditions specified in the protocol - Patient has any alarm symptoms including but not limited to GI bleeding, anemia, vomiting, dysphagia, or unexpected weight loss any time during the Screening or Pretreatment Periods - Patient has a history of clinically significant hypersensitivity or allergies to any of the excipients contained in the study medication (active or placebo). NOTE: Additional inclusion/exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
United States | IW-3718 Investigator | Anaheim | California |
United States | IW-3718 Investigator | Annapolis | Maryland |
United States | IW-3718 Investigator | Asheville | North Carolina |
United States | IW-3718 Investigator | Baltimore | Maryland |
United States | IW-3718 Investigator | Bowling Green | Kentucky |
United States | IW-3718 Investigator | Bristol | Connecticut |
United States | IW-3718 Investigator | Carmichael | California |
United States | IW-3718 Investigator | Charleston | South Carolina |
United States | IW-3718 Investigator | Chattanooga | Tennessee |
United States | IW-3718 Investigator | Chesterfield | Michigan |
United States | IW-3718 Investigator | Chevy Chase | Maryland |
United States | IW-3718 Investigator | Christiansburg | Virginia |
United States | IW-3718 Investigator | Chula Vista | California |
United States | IW-3718 Investigator | Cleveland | Ohio |
United States | IW-3718 Investigator | Clive | Iowa |
United States | IW-3718 Investigator | Columbus | Ohio |
United States | IW-3718 Investigator | DeLand | Florida |
United States | IW-3718 Investigator | Dothan | Alabama |
United States | IW-3718 Investigator | Egg Harbor Township | New Jersey |
United States | IW-3718 Investigator | El Paso | Texas |
United States | IW-3718 Investigator | Fargo | North Dakota |
United States | IW-3718 Investigator | Germantown | Tennessee |
United States | IW-3718 Investigator | Great Neck | New York |
United States | IW-3718 Investigator | Great Neck | New York |
United States | IW-3718 Investigator | Hollywood | Florida |
United States | IW-3718 Investigator | Houston | Texas |
United States | IW-3718 Investigator | Inverness | Florida |
United States | IW-3718 Investigator | Jupiter | Florida |
United States | IW-3718 Investigator | Kew Gardens | New York |
United States | IW-3718 Investigator | La Mirada | California |
United States | IW-3718 Investigator | Las Vegas | Nevada |
United States | IW-3718 Investigator | Lauderdale Lakes | Florida |
United States | IW-3718 Investigator | Lima | Ohio |
United States | IW-3718 Investigator | Lynchburg | Virginia |
United States | IW-3718 Investigator | Miami | Florida |
United States | IW-3718 Investigator | Miami | Florida |
United States | IW-3718 Investigator | Miami Lakes | Florida |
United States | IW-3718 Investigator | Mission Hills | California |
United States | IW-3718 Investigator | Monroe | Louisiana |
United States | IW-3718 Investigator | Nashville | Tennessee |
United States | IW-3718 Investigator | New York | New York |
United States | IW-3718 Investigator | Newport Beach | California |
United States | IW-3718 Investigator | Norman | Oklahoma |
United States | IW-3718 Investigator | North Little Rock | Arkansas |
United States | IW-3718 Investigator | Oakland | California |
United States | IW-3718 Investigator | Oklahoma City | Oklahoma |
United States | IW-3718 Investigator | Phoenix | Arizona |
United States | IW-3718 Investigator | Pittsburgh | Pennsylvania |
United States | IW-3718 Investigator | Port Orange | Florida |
United States | IW-3718 Investigator | Raleigh | North Carolina |
United States | IW-3718 Investigator | Reno | Nevada |
United States | IW-3718 Investigator | Sacramento | California |
United States | IW-3718 Investigator | San Antonio | Texas |
United States | IW-3718 Investigator | San Antonio | Texas |
United States | IW-3718 Investigator | San Diego | California |
United States | IW-3718 Investigator | Sandy | Utah |
United States | IW-3718 Investigator | South Ogden | Utah |
United States | IW-3718 Investigator | Tucson | Arizona |
United States | IW-3718 Investigator | Tucson | Arizona |
United States | IW-3718 Investigator | Tucson | Arizona |
United States | IW-3718 Investigator | Waterbury | Connecticut |
United States | IW-3718 Investigator | Wyoming | Michigan |
Lead Sponsor | Collaborator |
---|---|
Ironwood Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Change From Baseline to Week 8 in Weekly Heartburn Severity Score (WHSS) | The WHSS for an analysis week was defined as the average of available DHSS during that week. DHSS was defined as the maximum on a 6-point scale (0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe) of the 3 items measuring heartburn ( "Heartburn," "Burning feeling behind breastbone or in the center of the upper stomach," and "Pain behind breastbone or in the center of the upper stomach,") from a particular day. A negative change from Baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Week 8 | |
Secondary | Percent Change From Baseline to Week 4 in WHSS | The WHSS for an analysis week was defined as the average of available DHSS during that week. DHSS was defined as the maximum on a 6-point scale (0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe) of the 3 items measuring heartburn ( "Heartburn," "Burning feeling behind breastbone or in the center of the upper stomach," and "Pain behind breastbone or in the center of the upper stomach,") from a particular day. A negative change from Baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Week 4 | |
Secondary | Change From Baseline to Week 8 in WHSS | The WHSS for an analysis week was defined as the average of available DHSS during that week. DHSS was defined as the maximum on a 6-point scale (0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe) of the 3 items measuring heartburn ( "Heartburn," "Burning feeling behind breastbone or in the center of the upper stomach," and "Pain behind breastbone or in the center of the upper stomach,") from a particular day. A negative change from Baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Week 8 | |
Secondary | Change From Baseline to Week 4 in WHSS | The WHSS for an analysis week was defined as the average of available DHSS during that week. DHSS was defined as the maximum on a 6-point scale (0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe) of the 3 items measuring heartburn ( "Heartburn," "Burning feeling behind breastbone or in the center of the upper stomach," and "Pain behind breastbone or in the center of the upper stomach,") from a particular day. A negative change from Baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Week 4 | |
Secondary | Percentage of Participants Who Are Overall Heartburn Responders | An overall heartburn responder is a participant who is a weekly heartburn responder for at least 4 of the 8 treatment weeks and for at least 1 of the final 2 treatment weeks (i.e., Week 7 and Week 8). A weekly heartburn responder is a participant with a decrease of >= 30% from baseline in WHSS (see Outcome Measure 1 for description of WHSS). A participant who reported heartburn severity for less than 4 days during a week was not considered a responder for that week. | Week 8 | |
Secondary | Percentage of Participants With a DHSS of No More Than Very Mild (= 1) on Any Day During Week 8 | DHSS was defined as the maximum on a 6-point scale (0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe) of the 3 items measuring heartburn ( "Heartburn," "Burning feeling behind breastbone or in the center of the upper stomach," and "Pain behind breastbone or in the center of the upper stomach,") from a particular day. A participant who reported heartburn severity for less than 4 days during a week was not considered a responder for that week. | Week 8 | |
Secondary | Percentage of Participants With a DHSS of No More Than Very Mild (= 1) on Any Day During Week 4 | DHSS was defined as the maximum on a 6-point scale (0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe) of the 3 items measuring heartburn ( "Heartburn," "Burning feeling behind breastbone or in the center of the upper stomach," and "Pain behind breastbone or in the center of the upper stomach,") from a particular day. A participant who reported heartburn severity for less than 4 days during a week was not considered a responder for that week. | Week 4 | |
Secondary | Change From Baseline in the Number of Days Where DHSS Was No More Than Very Mild (= 1) During Week 8 | DHSS was defined as the maximum on a 6-point scale (0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe) of the 3 items measuring heartburn ( "Heartburn," "Burning feeling behind breastbone or in the center of the upper stomach," and "Pain behind breastbone or in the center of the upper stomach,") from a particular day. | Week 8 | |
Secondary | Change From Baseline in the Number of Days Where DHSS Was No More Than Very Mild (= 1) During Week 4 | DHSS was defined as the maximum on a 6-point scale (0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe) of the 3 items measuring heartburn ( "Heartburn," "Burning feeling behind breastbone or in the center of the upper stomach," and "Pain behind breastbone or in the center of the upper stomach,") from a particular day. | Week 4 | |
Secondary | Change From Baseline Over Time in the Weekly Average of Modified Reflux Symptom Questionnaire - Electronic Diary (mRESQ-eD) Item 'Heartburn Severity' | The mRESQ-eD questionnaire assesses the severity and frequency of the symptoms participants experience due to reflux disease. Participants were asked to rate the severity of their heartburn over the past 24 hours on a 6-point scale: 0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe. Daily scores were averaged each week. A negative change from Baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Weeks 1, 2, 3, 4, 5, 6, 7, 8 | |
Secondary | Change From Baseline Over Time in the Weekly Average of mRESQ-eD Item 'Burning Feeling Behind Breastbone or Center of Upper Stomach Severity' | The mRESQ-eD questionnaire assesses the severity and frequency of the symptoms participants experience due to reflux disease. Participants were asked to rate the severity of their burning feeling behind the breastbone or in the center of the upper stomach over the past 24 hours on a 6-point scale: 0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe. Daily scores were averaged each week. A negative change from baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Weeks 1, 2, 3, 4, 5, 6, 7, 8 | |
Secondary | Change From Baseline Over Time in the mRESQ-eD Item 'Pain Behind Breastbone or Center of Upper Stomach Severity' | The mRESQ-eD questionnaire assesses the severity and frequency of the symptoms participants experience due to reflux disease. Participants were asked to rate the severity of their pain behind the breastbone or in the center of the upper stomach over the past 24 hours on a 6-point scale: 0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe. Daily scores were averaged each week. A negative change from baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Weeks 1, 2, 3, 4, 5, 6, 7, 8 | |
Secondary | Change From Baseline Over Time in the mRESQ-eD Item 'Difficulty Swallowing Severity' | The mRESQ-eD questionnaire assesses the severity and frequency of the symptoms participants experience due to reflux disease. Participants were asked to rate the severity of their difficulty swallowing over the past 24 hours on a 6-point scale: 0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe. Daily scores were averaged each week. A negative change from baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Weeks 1, 2, 3, 4, 5, 6, 7, 8 | |
Secondary | Change From Baseline Over Time in the mRESQ-eD Item 'Hoarseness Severity' | The mRESQ-eD questionnaire assesses the severity and frequency of the symptoms participants experience due to reflux disease. Participants were asked to rate the severity of their hoarseness over the past 24 hours on a 6-point scale: 0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe. Daily scores were averaged each week. A negative change from baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Weeks 1, 2, 3, 4, 5, 6, 7, 8 | |
Secondary | Change From Baseline Over Time in the mRESQ-eD Item 'Cough Severity' | The mRESQ-eD questionnaire assesses the severity and frequency of the symptoms participants experience due to reflux disease. Participants were asked to rate the severity of their cough over the past 24 hours on a 6-point scale: 0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe. Daily scores were averaged each week. A negative change from baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Weeks 1, 2, 3, 4, 5, 6, 7, 8 | |
Secondary | Change From Baseline Over Time in the mRESQ-eD Item 'Regurgitation Frequency' | The mRESQ-eD questionnaire assesses the severity and frequency of the symptoms participants experience due to reflux disease. Participants were asked to rate the frequency of their regurgitation (liquid or food moving upwards towards the throat or mouth) over the past 24 hours on a 5-point scale: 0=Never, 1= Rarely, 2=Sometimes, 3=Often, 4=Very often. Daily scores were averaged each week. A negative change from baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Weeks 1, 2, 3, 4, 5, 6, 7, 8 | |
Secondary | Change From Baseline Over Time in the mRESQ-eD Item 'Acid or Bitter Taste Frequency' | The mRESQ-eD questionnaire assesses the severity and frequency of the symptoms participants experience due to reflux disease. Participants were asked to rate the frequency of an acid or bitter taste in the mouth over the past 24 hours on a 5-point scale: 0=Never, 1= Rarely, 2=Sometimes, 3=Often, 4=Very often. Daily scores were averaged each week. A negative change from baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Weeks 1, 2, 3, 4, 5, 6, 7, 8 | |
Secondary | Change From Baseline Over Time in the mRESQ-eD Item 'Coughing Frequency' | The mRESQ-eD questionnaire assesses the severity and frequency of the symptoms participants experience due to reflux disease. Participants were asked to rate the frequency of their cough over the past 24 hours on a 5-point scale: 0=Never, 1= Rarely, 2=Sometimes, 3=Often, 4=Very often. Daily scores were averaged each week. A negative change from baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Weeks 1, 2, 3, 4, 5, 6, 7, 8 | |
Secondary | Change From Baseline Over Time in the mRESQ-eD Item 'Burping Frequency' | The mRESQ-eD questionnaire assesses the severity and frequency of the symptoms participants experience due to reflux disease. Participants were asked to rate the frequency of their burping over the past 24 hours on a 5-point scale: 0=Never, 1= Rarely, 2=Sometimes, 3=Often, 4=Very often. Daily scores were averaged each week. A negative change from baseline indicates improvement. | Baseline (derived from the eDiary daily data collected from 7 days before randomization up to the time of randomization), Weeks 1, 2, 3, 4, 5, 6, 7, 8 | |
Secondary | Change From Baseline in the Proportion of Heartburn-Free Days During Week 8 | A heartburn free day was a day where DHSS = 0. DHSS was defined as the maximum on a 6-point scale (0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe) of the 3 items measuring heartburn ( "Heartburn," "Burning feeling behind breastbone or in the center of the upper stomach," and "Pain behind breastbone or in the center of the upper stomach,") from a particular day. | Week 8 | |
Secondary | Change From Baseline in the Proportion of Heartburn-Free Days During Week 4 | A heartburn free day was a day where DHSS = 0. DHSS was defined as the maximum on a 6-point scale (0=Did Not Have, 1=Very Mild, 2=Mild, 3=Moderate, 4=Moderately Severe, 5=Severe) of the 3 items measuring heartburn ( "Heartburn," "Burning feeling behind breastbone or in the center of the upper stomach," and "Pain behind breastbone or in the center of the upper stomach,") from a particular day. | Week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02135107 -
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
|
Phase 3 | |
Completed |
NCT01432392 -
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Recruiting |
NCT01249482 -
Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
|
N/A | |
Completed |
NCT01578642 -
Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease
|
Phase 2 | |
Completed |
NCT01200550 -
The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients
|
N/A | |
Completed |
NCT00978016 -
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
|
Phase 2 | |
Unknown status |
NCT01128608 -
The Effect of High PCO2 Solution on Esophageal Acid Sensation
|
N/A | |
Completed |
NCT00998244 -
Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT00768443 -
Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)
|
N/A | |
Completed |
NCT00768196 -
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients
|
N/A | |
Recruiting |
NCT00498082 -
Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease
|
N/A | |
Completed |
NCT00886197 -
Diagnostic Efficacy of Narrow Band Imaging in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT00378898 -
Feasibility of Placing Bravo PH Capsule in Proximal Esophagus
|
N/A | |
Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
Completed |
NCT00507377 -
Foreshortened Esophagus and Its Surgical Therapy
|
||
Completed |
NCT00165022 -
Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population
|
N/A | |
Completed |
NCT00214552 -
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
|
Phase 3 | |
Completed |
NCT00625495 -
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
|
Phase 4 | |
Completed |
NCT00618150 -
Patient Education in Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT03299985 -
Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease
|
N/A |